Daily Bulletin

Business News

  • Written by NewsServices.com

Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that the Victorian Government has granted A$1.45M to Noxopharm collaborator, Hudson Institute of Medical Research, to fund the joint development program of novel anti-inflammatory compounds. Noxopharm’s wholly-owned subsidiary, Victoria-registered Pharmorage Pty Ltd, is named on the grant as the collaborator that will design and synthetise the compounds with the view of commercialising any promising drug candidates generated by the research. 

The research aims to identify novel drug compounds that dampen harmful excessive inflammation associated with COVID-19 infection. Should any identified drug candidates show promise of broader inflammatory indications it is anticipated that Noxopharm will investigate their commercial and scientific potential. 

Reducing excessive inflammation during COVID-19 infection is a critical part of limiting virus[1]associated hospitalisations, intensive care admissions, and deaths. In addition, mounting evidence suggests that chronic inflammation underpins post-infectious syndromes associated with long-COVID, which may impact as many as 60% of COVID-19 patients.1 Therefore, this research aims to fast-track the therapeutic development of new, targeted therapies to help manage both acute and chronic inflammation. 

Noxopharm CEO Dr Gisela Mautner, said: “Noxopharm has built a network of collaborators spanning world-renowned academic and government institutions, including Hudson Institute. We are excited the collaboration with Hudson Institute is attracting this level of non-dilutive funding. We look forward to progressing our work in inflammatory diseases with them.” The research is set to commence shortly and will continue for approximately two years. Noxopharm will continue to keep the market informed as this work progresses. 

1 Blomberg, B., Mohn, K.GI., Brokstad, K.A. et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med 27, 1607–1613 (2021). https://doi.org/10.1038/s41591-021-01433-3


Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that the Victorian Government has granted A$1.45M to Noxopharm collaborator, Hudson Institute of Medical Research, to fund the joint development program of novel anti-inflammatory compounds. Noxopharm’s wholly-owned subsidiary, Victoria-registered Pharmorage Pty Ltd, is named on the grant as the collaborator that will design and synthetise the compounds with the view of commercialising any promising drug candidates generated by the research. 

The research aims to identify novel drug compounds that dampen harmful excessive inflammation associated with COVID-19 infection. Should any identified drug candidates show promise of broader inflammatory indications it is anticipated that Noxopharm will investigate their commercial and scientific potential. 

Reducing excessive inflammation during COVID-19 infection is a critical part of limiting virus[1]associated hospitalisations, intensive care admissions, and deaths. In addition, mounting evidence suggests that chronic inflammation underpins post-infectious syndromes associated with long-COVID, which may impact as many as 60% of COVID-19 patients.1 Therefore, this research aims to fast-track the therapeutic development of new, targeted therapies to help manage both acute and chronic inflammation. 

Noxopharm CEO Dr Gisela Mautner, said: “Noxopharm has built a network of collaborators spanning world-renowned academic and government institutions, including Hudson Institute. We are excited the collaboration with Hudson Institute is attracting this level of non-dilutive funding. We look forward to progressing our work in inflammatory diseases with them.” The research is set to commence shortly and will continue for approximately two years. Noxopharm will continue to keep the market informed as this work progresses. 

1 Blomberg, B., Mohn, K.GI., Brokstad, K.A. et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med 27, 1607–1613 (2021). https://doi.org/10.1038/s41591-021-01433-3

Young women's memoirs of migration, dispossession and Australian 'unbelonging' demand to be heard

arrow_forward

How Business Permit Processing Works in the Philippines

Are you an aspiring new business owner? A business permit is a must for any establishment here in the Philippines. Without it, you have no legal right to run one. But do you know how the permit pr...

Angelo Castelda - avatar Angelo Castelda

How to Make the Right First Impression on Clients Who Visit Your Office

Your office says a lot about your company, and clients will make plenty of assumptions about your business based on their experience visiting your place of work. That's why it's important to make a ...

NewsServices.com - avatar NewsServices.com

Latin America best link building agencies

Nowadays, making your site visible on searching engines is one of the most important goals in order to attract customers to your business. Having a website that can’t be found within the first page...

NewsServices.com - avatar NewsServices.com

6 Things You Need to Host a Successful Business Party

A successful business party provides a fun and memorable experience for all who attend. It can be a great opportunity to promote your company and network with potential clients and partners. But to ...

Daily Bulletin - avatar Daily Bulletin

$1.45M Grant to Hudson Institute for Collaboration with Noxopharm

Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that the Victorian Government has granted A$1.45M to Noxopharm collaborator, Hudson Institute of Medical Research, to ...

NewsServices.com - avatar NewsServices.com

Government SME Recovery Loan Scheme due to close end of June 2022

Australia’s leading business finance provider, Earlypay, is encouraging businesses to take advantage of the government’s generous SME Recovery Loan Scheme before applications close on 30 June 2022...

Tess Sanders Lazarus - avatar Tess Sanders Lazarus


The Conversation